Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.788770
Keywords
boron neutron capture therapy (BNCT); thermal neutron; boron delivery agent; radiation; tumor
Categories
Funding
- Special Research Project of Lanzhou University Serving the Economic Social Development of Gansu Province [054000282]
- Lanzhou Talent Innovation and Entrepreneurship Project [2020-RC-38]
- Fundamental Research Funds for the Central Universities [lzujbky-2020-kb14]
- Major Science and Technology Special Project of Gansu Province [20ZD7FA003]
Ask authors/readers for more resources
Boron neutron capture therapy (BNCT) is an emerging therapy that selectively kills tumor cells by using boron delivery agents to release alpha and lithium particles through neutron-triggered fission. It has been developed for the treatment of various cancers and requires further research on efficient delivery agents and accurate dose measurement systems.
Boron neutron capture therapy (BNCT) is a re-emerging therapy with the ability to selectively kill tumor cells. After the boron delivery agents enter the tumor tissue and enrich the tumor cells, the thermal neutrons trigger the fission of the boron atoms, leading to the release of boron atoms and then leading to the release of the alpha particles (He-4) and recoil lithium particles (Li-7), along with the production of large amounts of energy in the narrow region. With the advantages of targeted therapy and low toxicity, BNCT has become a unique method in the field of radiotherapy. Since the beginning of the last century, BNCT has been emerging worldwide and gradually developed into a technology for the treatment of glioblastoma multiforme, head and neck cancer, malignant melanoma, and other cancers. At present, how to develop and innovate more efficient boron delivery agents and establish a more accurate boron-dose measurement system have become the problem faced by the development of BNCT. We discuss the use of boron delivery agents over the past several decades and the corresponding clinical trials and preclinical outcomes. Furthermore, the discussion brings recommendations on the future of boron delivery agents and this therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available